Physician profile
Karl Timothy Chen
NPI 1982600169
$11,987.57
in general payments reported to CMS, 2019-2025
44 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,360 · 2020: $2,112 · 2021: $2,866 · 2022: $1,832 · 2023: $1,471 · 2024: $918 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Education: $23.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.11 |
| Education | $23.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $1,742.09 | 2019-2024 | Livalo, Seglentis |
| Amarin Pharma, INC. | $1,241.91 | 2019-2023 | |
| Abbvie INC. | $1,117.47 | 2019-2025 | Qulipta, Ubrelvy, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.13 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $760.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $702.94 | 2019-2022 | |
| Amgen INC. | $674.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $505.70 | 2019-2025 | Capvaxive |
| Allergan, INC. | $500.08 | 2019-2020 | |
| Pfizer INC. | $435.44 | 2019-2021 | |
| Antares Pharma, INC. | $433.72 | 2019-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $387.89 | 2019-2023 | |
| Tolmar, INC. | $354.39 | 2023-2025 | Jatenzo |
| Biohaven Pharmaceuticals, INC. | $234.37 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $199.96 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.